ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Comorbidity"

  • Abstract Number: 2163 • 2015 ACR/ARHP Annual Meeting

    Associations Between Sex Differences, Pain, Insomnia, and Depression in Older Adults with Osteoarthritis: A Cross-Sectional Study

    Minhui Liu1, Susan McCurry1, Michael Vitiello2, Basia Belza1 and Michael Von Korff3, 1University of Washington School of Nursing, Seattle, WA, 2Psychiatry and Behavioral Sciences, Biobehavioral Nursing and Health Systems, University of Washington School of Medicine, Seattle, WA, 3Group Health Research Institute, Seattle, WA

    Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis and affects nearly 30 million Americans. Chronic pain is the major symptom in OA and…
  • Abstract Number: 2878 • 2015 ACR/ARHP Annual Meeting

    Treating Axial Spondyloarthritis to Target: Influence of the Population Characteristics and Comorbidities in Reaching Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Tnfalpha Inhibitors Agents

    Sara Monti, Veronica Codullo, Vittorio Grosso, Silvia Breda, Carlomaurizio Montecucco and Roberto Caporali, Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy

    Background/Purpose: The treat to target strategy (T2T), aiming at inactive disease (ID), has become the recommended approach also in the field of axial-SpA (axSpA) (1). …
  • Abstract Number: 3086 • 2015 ACR/ARHP Annual Meeting

    The Same Multidimensional Patient Health Assessment Questionnaire Used to Assess RAPID3 in Rheumatoid Arthritis, Osteoarthritis and Other Rheumatic Diseases Can Provide Quantitative Clues to Recognize and Document Comorbid Fibromyalgia

    Kathryn A. Gibson1, Annie Huang2 and Theodore Pincus2, 1Liverpool Hospital, Liverpool, Australia, 2Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: An MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) is a 2 sided, 1 page questionnaire which is completed by patients in…
  • Abstract Number: 3119 • 2015 ACR/ARHP Annual Meeting

    The Risk of Venous Thromboembolism in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis

    Alexis Ogdie-Beatty1, Daniel Shin2, Junko Takeshita2, Zelma ChiesaFuxench2 and Joel Gelfand3, 1Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania Health System , Philadelphia, PA

    Background/Purpose: Venous thromboembolism (VTE), the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially deadly medical problem with…
  • Abstract Number: 3120 • 2015 ACR/ARHP Annual Meeting

    The Prevalence, Incidence and Management of Hypertension, Diabetes and Hyperlipidemia in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis

    Kashif Jafri1, Christie M. Bartels2, Daniel Shin3 and Alexis Ogdie-Beatty4, 1Department of Medicine, University of Pennsylvania, Philadelphia, PA, 2Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, 3University of Pennsylvania, Philadelphia, PA, 4Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis (RA) are associated with an increased risk for cardiovascular disease (CVD).  While management of traditional CVD risk…
  • Abstract Number: 3258 • 2015 ACR/ARHP Annual Meeting

    Different Perception of Disease Activity in Multimorbid Rheumatoid Arthritis Patients

    Helga Radner1,2, Kazuki Yoshida1,3, Sara K. Tedeschi4, M Frits5, C Iannaccone6, N Shadick7, Michael Weinblatt1, Daniel Aletaha8, Josef S. Smolen9 and Daniel H. Solomon10, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Department of Epidemiology, Harvard School of Public Health, Boston, MA, 4Rheumatology, Brigham & Women's Hospital, Boston, MA, 5Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 6Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 7Division of Rheumatology, Immunology & Allergy, Brigham and Women's Hosp, Boston, MA, 8Rheumatology, Medical University Vienna, Vienna, Austria, 9Dept of Medicine 3, Division of Rheumatology, Medical Univ Vienna, Vienna, Austria, 10Rheumatology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: The patient rating of global rheumatoid arthritis (RA) disease activity (PtGA) is a key variable in composite measures of disease activity as well as…
  • Abstract Number: 2114 • 2014 ACR/ARHP Annual Meeting

    Comorbidity Characteristics of Patients Starting First-Line Acute Gout Agents – Colchicine, NSAID, and Corticosteroids

    Alfonso Perez1, Robert Jackson2, Jiao Yang3, Aki Shiozawa4, Shawn Yu4, Yimin Qin1, Huifang Liang5 and Hyon K. Choi6, 1Global Clinical Science, Takeda Pharmaceuticals International, Inc, Deerfield, IL, 2Global Medical Office, Takeda Pharmaceuticals International, Inc, Deerfield, IL, 3Analytical Science, Takeda Pharmaceuticals International, Inc, Deerfield, IL, 4Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, 5Pharmacovigilance, Takeda Pharmaceuticals International, Inc, Deerfield, IL, 6Boston University School of Medicine, Boston, MA

    Comorbidity Characteristics of Patients Starting First-Line Acute Gout Agents - Colchicine, NSAID, and CorticosteroidsBackground/Purpose: There is a remarkable, increasing disease burden of gout and its…
  • Abstract Number: 2054 • 2014 ACR/ARHP Annual Meeting

    Physical and Mental Functioning in Patients with Established Rheumatoid Arthritis over an 11-Year Follow-up Period: The Role of Specific Comorbidities

    Joëlle van den Hoek1, Leo D. Roorda2, Hendriek C. Boshuizen3, Gerard J. Tijhuis4, Trudi van den Bos5 and Joost Dekker6, 1Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, 2Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, 3National Institute of Public Health and the Environment, Bilthoven, Netherlands, 4Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 5Social Medicine, Academic Medical Center, Amsterdam, Netherlands, 6Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose Comorbidity in patients with Rheumatoid Arthritis (RA) is highly prevalent and plays an important role in determining RA related outcomes. Several studies have reported…
  • Abstract Number: 2029 • 2014 ACR/ARHP Annual Meeting

    Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study

    Helga Radner1,2, Kazuki Yoshida3,4, Ihsane Hmamouchi5, Maxime Dougados6,7, Josef Smolen8 and Daniel H Solomon9, 1Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, 4Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, 5Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, 6Descartes University, Cochin Hospital, Paris, France, 7INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, 8Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 9Rheumatology, Brigham and Women's Hospital, Boston, MA

    Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-sectional StudyBackground/Purpose The presence of multimorbidity could lead to less intensive treatment of RA.…
  • Abstract Number: 1771 • 2014 ACR/ARHP Annual Meeting

    Arterial Thrombotic Events in Systemic Vasculitis

    Alexander Tsoukas1, Sasha Bernatsky2, Lawrence Joseph3, David Buckeridge4, Patrick Belisle5 and Christian A. Pineau1, 1Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 2Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 3McGill University, Montreal, QC, Canada, 4Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada, 5Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose To estimate the incidence rate of clinically apparent arterial thrombotic events and associated comorbidities in patients with primary systemic vasculitis. Methods Using large-cohort administrative…
  • Abstract Number: 1570 • 2014 ACR/ARHP Annual Meeting

    Relationship Between Psoriatic Arthritis Severity, Duration, and Comorbidities

    Stacy Tanner1, Molly McFadden2, Daniel Clegg3 and Jessica Walsh4, 1Internal Medicine, University of Utah, Salt Lake City, UT, 2Internal Medicine-Division of Epidemiology, University of Utah, SLC, UT, 3Division of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT, 4Rheumatology Room 4B200 School of Medicine, University of Utah, Salt Lake City, UT

    Background/Purpose People with psoriatic arthritis (PsA) have an increased risk for several comorbidities that negatively impact quality of life and survival.  Defining the relationships between…
  • Abstract Number: 1279 • 2014 ACR/ARHP Annual Meeting

    Pre-Operative Musculoskeletal Comorbidities Limit Improvement in Functional Outcomes and Hip Pain in Total Hip Arthroplasty Patients

    Scott Pascal1, David Ayers2, Wenjun Li2, Leslie Harrold3, Jeroan Allison4 and Patricia D. Franklin2, 1University of Massachusetts Medical School, Worcester, MA, 2Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, 3Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, 4Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA

    Pre-Operative Musculoskeletal Comorbidities Limit Improvement In Functional Outcomes And Hip Pain In Total Hip Arthroplasty PatientsBackground/Purpose:   Identifying clinical factors predictive of total hip arthroplasty…
  • Abstract Number: 1053 • 2014 ACR/ARHP Annual Meeting

    Co-Morbidity Is Associated with Disease Severity in Early Rheumatoid Arthritis

    Christopher Sparks1, Aleena Abdullah2, Steven Zhao3, Cristina Estrach3 and Nicola Goodson1, 1Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, 2Musculoskeletal biology1, University of Liverpool, Liverpool, United Kingdom, 3Rheumatology, University Hospital Aintree, Liverpool, United Kingdom

    Background/Purpose Co-morbidity has been shown to increase length of hospital stay and mortality in hospitalised patients. However, in early rheumatoid arthritis (eRA) co-morbidity may confound…
  • Abstract Number: 105 • 2014 ACR/ARHP Annual Meeting

    Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey

    Robert Morlock1, Natalia M. Flores2, Kathy Annunziata3, J. Chapnick4 and Sulabha Ramachandran5, 14939 Directors Place, Ardea Biosciences, San Diego, CA, 2Kantar Health, Foster City, CA, 3Kantar Health, Princeton, NJ, 4Kantar Health, Horsham, PA, 5AstraZeneca, Wilmington, DE

    Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal…
  • Abstract Number: 2137 • 2013 ACR/ARHP Annual Meeting

    Important Predictors Of Patient-Reported Outcomes After TKR and THR Are Not Included In Risk Models Based On Administrative Data

    Patricia D. Franklin1, Leslie R. Harrold2, Wenjun Li1, Jeroan Allison3, David Ayers1 and Courtland Lewis4, 1Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, 2University of Massachusetts Medical School, Worcester, MA, 3Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, 4Hartford Hospital, Hartford, CT

    Background/Purpose: Because total knee (TKR) and total hip (THR) replacement surgery is performed to relieve pain and improve physical function in patients with advanced arthritis,…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology